Close
Osman Kibar, Ph.D.

Osman Kibar, Ph.D.

Dr. Kibar is an entrepreneur and an inventor, with numerous successful start-ups under his belt. He was the Scientific Founder of Genoptix (an oncology diagnostics company), which went public in 2007 (NASDAQ: GXDX) and was later acquired by Novartis in 2011. Dr. Kibar was also a Co-Founder of E-Tenna, whose assets relating to wireless antennas were acquired by Titan and assets relating to thermal management of microprocessors by Intel. He was a Vice President at Pequot Capital's venture capital and private equity team. Dr. Kibar received his M.S. and Ph.D., specializing in Biophotonics and Optoelectronics, from University of California, San Diego, a B.S. in Electrical Engineering from Caltech and a B.A. in Mathematical Economics from Pomona College.

Cevdet Samikoglu

Cevdet Samikoglu

Mr. Samikoglu is a public and private investor, entrepreneur and a former investment banker. He was the Co-Founder, Portfolio Manager and a Partner of Greywolf Capital Management LP, a New York-based investment fund managing capital in different strategies. Previously, Mr. Samikoglu spent his career at Goldman, Sachs & Co. for nine years, both as a proprietary investor and as an investment banker. Prior to forming Greywolf, he was the Director of Research and a Portfolio Manager of Goldman Sachs’ Special Situations Investing Group. Mr. Samikoglu received his M.B.A. from Harvard Business School and a B.A. in Economics from Hamilton College.

Yusuf Yazici, M.D.

Yusuf Yazici, M.D.

Dr. Yazici is an internationally-renowned rheumatologist, researcher, and an expert in clinical trial design and management. He is a Clinical Associate Professor at NYU and the Director of Seligman Center for Advanced Therapeutics, which conducts all clinical trials in rheumatology at the NYU Hospital for Joint Diseases. Dr. Yazici is also the Director of Behcet’s Syndrome Center, the largest center for Behcet’s Disease in the US. He has published more than 250 medical papers and book chapters, and has given numerous national and international presentations. Dr. Yazici completed his Fellowship in Rheumatology at the Hospital for Special Surgery of Weill Medical College of Cornell University in New York and Residency in Internal Medicine at Creighton University in Nebraska. Dr. Yazici received his medical degree from Istanbul University.

Arman Oruc

Arman Oruc

Mr. Oruc was a Partner and a Co-Founder of the Washington, D.C. office of Simpson Thacher & Bartlett LLP. He has represented clients from a wide range of industries including numerous Fortune 500 companies and has been recognized for his expertise by numerous trade publications, including Chambers and WhosWhoLegal. In addition to regulatory work in front of U.S. and non-U.S. agencies, he has handled business-critical litigations involving intellectual property and antitrust laws, and has advised on marketing, pricing, product roadmaps, as well as dealings with competitors. Mr. Oruc received his J.D. from the University of California, Berkeley, M.Phil. in Economics from Cambridge University and a B.A. in Economics from Skidmore College.

Osman Kibar, Ph.D.

John Hood, Ph.D.

Dr. Hood was a Co-Founder and the Director of Research of TargeGen, Inc. (a drug development company focused on small molecules) where he led a number of drug programs into the clinic in oncology, ophthalmology and cardiology. After TargeGen’s acquisition by Sanofi-aventis, Dr. Hood joined Samumed as the Chief Scientific Officer. Dr. Hood has authored numerous peer-reviewed articles and patents in areas including cell signaling and medicinal chemistry in a number of therapeutic areas. Dr. Hood completed his Postdoctoral Fellowship at The Scripps Research Institute. He received his Ph.D. in Physiology and a B.S. in Biochemistry from Texas A&M University.

Erich Horsley

Erich Horsley

Mr. Horsley has two decades of experience building businesses as a private equity investor and entrepreneur. Most recently, he was a Partner and a founding member of Intervale Capital, a Boston-based private equity firm with multiple funds under management. Previously, Mr. Horsley worked as a Principal at Watermill Group, a generalist private equity firm, and as an investment banker at Morgan Stanley in New York and Frankfurt. Mr. Horsley has an M.B.A. from Harvard Business School and an A.B. in Psychology and English from Harvard College.

Blake Mobley, Ph.D.

Blake Mobley, Ph.D.

Dr. Mobley was previously a Counterintelligence Analyst at the Central Intelligence Agency, where he served tours in the Middle East and Langley, Virginia. At the CIA he supported clandestine operations and produced analytic reports for senior US policymakers, including two Presidents and their cabinets. More recently, Dr. Mobley served as Co-Founder and CEO of Threat Pattern, LLC, a firm that collected and analyzed “big data” sources to support intelligence, counterintelligence, public relations and security operations for corporate and government clients. Before founding Threat Pattern, he worked at the RAND Corporation as a Political Analyst where he focused on counterintelligence theory and practice. Dr. Mobley has a Ph.D. in Political Science from Georgetown University, an M.P.P. in Public Policy from Harvard University, and a B.A. in Psychology from Stanford University.

Philippe Marchand, Ph.D.

Philippe Marchand, Ph.D.

Dr. Marchand is an operations executive and an entrepreneur. Previously, Dr. Marchand was the CIO of Genoptix (a subsidiary of Novartis) and assumed responsibilities for global IT operations with Novartis Oncology. At Genoptix, he initially led the engineering development and operations and subsequently, as CIO, oversaw the creation of the Diagnostics Laboratory, the subsequent IPO, and the acquisition of Genoptix by Novartis. Earlier in his career, Dr. Marchand founded two San Diego-based technology companies, Celula and Parallel Solutions, where he also assumed roles of CTO and President, respectively. Dr. Marchand received a M.S. (Hons.), a Ph.D., and the Research Habilitation in Electrical Engineering from the Université de Haute Alsace, France and was a Lavoisier post-doctoral fellow at the University of California, San Diego.